Atara Biotherapeutics, Inc.
Atara Biotherapeutics develops therapies for solid tumors, hematologic cancers, and autoimmune diseases. Tab-cel, its lead product, is in Phase 3 trials for EBV-driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. The company has a CAR T immunotherapy pipeline with ATA3219 and ATA3431 in clinical/trial stages. ATA188 is in Phase 2 trials to treat multiple sclerosis. Atara also collaborates with Memorial Sloan Kettering Cancer Center and Queensland Institute of Medical Research. The company was incorporated in 2012 and is headquartered in California.
Overview
Strengths
- Creates economic value: ROIC of 100.0% against a cost of capital (WACC) of 17.6%, a spread of 82.4 percentage points.
- Our discounted cash flow model points to 218% upside (target price 25.01 USD), and even our pessimistic growth scenario implies 131%: a margin of safety.
- Valued below its Biotechnology peers: P/E 1.8x vs. a median of 20.4x and EV/EBITDA 1.5x vs. a median of 15.6x.
- ROIC of 100.0% beats 93% of its 128 Biotechnology peers (median 0.0%).
- Cheaper than its own history: P/E 1.8x vs. a historical average of 86.1x and EV/EBITDA 1.5x vs. a historical average of 86.0x.
Weaknesses
- Shareholder dilution: the share count has grown by 24.0% a year over the last three years.
- Unreliable cash generation: free cash flow was negative in 7 of the last 7 years.
- Unstable profitability: operating margin ranged from -3,219% to 30% over the last 5 years, with operating losses in 4 of them.
- Small company (enterprise value $60 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data